Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment.
OBJECTIVE: To assess Spanish and Portuguese patients' and physicians' preferences regarding type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain benefits or avoid side effects. METHODS: An observational, multicenter, exploratory study focused on routi...
| Autores: | , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2015 |
| País: | España |
| Institución: | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| Repositorio: | r-FISABIO. Repositorio Institucional de Producción Científica |
| OAI Identifier: | oai:fisabio.fundanetsuite.com:p4751 |
| Acceso en línea: | https://fisabio.portalinvestigacion.com/publicaciones/4751 |
| Access Level: | acceso abierto |
| Palabra clave: | HbA1c cardiovascular risk diabetes discrete choice model hypoglycemia preferences weight willingness to pay |
| id |
ES_12df8a23a4e9388f0147477c4ae4a2e6 |
|---|---|
| oai_identifier_str |
oai:fisabio.fundanetsuite.com:p4751 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment.Morillas, ArlosFeliciano, RosaFernndez Catalina, PabloPonte, CarlaBotella, MartaRodrigues, JoaoEsmatjes, EnricLafita, JavierLizan, LuisLlorente, IgnacioMorales, CristobalNavarro-Perez, JorgeOrozco-Beltran, DomingoPaz, SilviaRamirez de Arellano, AntonioCardoso, CristinaTribaldos Causadias, MaribelHbA1ccardiovascular riskdiabetesdiscrete choice modelhypoglycemiapreferencesweightwillingness to payOBJECTIVE: To assess Spanish and Portuguese patients' and physicians' preferences regarding type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain benefits or avoid side effects. METHODS: An observational, multicenter, exploratory study focused on routine clinical practice in Spain and Portugal. Physicians were recruited from multiple hospitals and outpatient clinics, while patients were recruited from eleven centers operating in the public health care system in different autonomous communities in Spain and Portugal. Preferences were measured via a discrete choice experiment by rating multiple T2DM medication attributes. Data were analyzed using the conditional logit model. RESULTS: Three-hundred and thirty (n=330) patients (49.7% female; mean age 62.4 [SD: 10.3] years, mean T2DM duration 13.9 [8.2] years, mean body mass index 32.5 [6.8] kg/m(2), 41.8% received oral + injected medication, 40.3% received oral, and 17.6% injected treatments) and 221 physicians from Spain and Portugal (62% female; mean age 41.9 [SD: 10.5] years, 33.5% endocrinologists, 66.5% primary-care doctors) participated. Patients valued avoiding a gain in bodyweight of 3 kg/6 months (WTP: €68.14 [95% confidence interval: 54.55-85.08]) the most, followed by avoiding one hypoglycemic event/month (WTP: €54.80 [23.29-82.26]). Physicians valued avoiding one hypoglycemia/week (WTP: €287.18 [95% confidence interval: 160.31-1,387.21]) the most, followed by avoiding a 3 kg/6 months gain in bodyweight and decreasing cardiovascular risk (WTP: €166.87 [88.63-843.09] and €154.30 [98.13-434.19], respectively). Physicians and patients were willing to pay €125.92 (73.30-622.75) and €24.28 (18.41-30.31), respectively, to avoid a 1% increase in glycated hemoglobin, and €143.30 (73.39-543.62) and €42.74 (23.89-61.77) to avoid nausea. CONCLUSION: Both patients and physicians in Spain and Portugal are willing to pay for the health benefits associated with improved diabetes treatment, the most important being to avoid hypoglycemia and gaining weight. Decreased cardiovascular risk and weight reduction became the third most valued attributes for physicians and patients, respectively.DOVE MEDICAL PRESS LTD2015info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/4751Patient Preference and AdherenceISSN: 1177889Xreponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p47512026-06-11T12:45:17Z |
| dc.title.none.fl_str_mv |
Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. |
| title |
Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. |
| spellingShingle |
Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Morillas, Arlos HbA1c cardiovascular risk diabetes discrete choice model hypoglycemia preferences weight willingness to pay |
| title_short |
Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. |
| title_full |
Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. |
| title_fullStr |
Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. |
| title_full_unstemmed |
Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. |
| title_sort |
Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. |
| dc.creator.none.fl_str_mv |
Morillas, Arlos Feliciano, Rosa Fernndez Catalina, Pablo Ponte, Carla Botella, Marta Rodrigues, Joao Esmatjes, Enric Lafita, Javier Lizan, Luis Llorente, Ignacio Morales, Cristobal Navarro-Perez, Jorge Orozco-Beltran, Domingo Paz, Silvia Ramirez de Arellano, Antonio Cardoso, Cristina Tribaldos Causadias, Maribel |
| author |
Morillas, Arlos |
| author_facet |
Morillas, Arlos Feliciano, Rosa Fernndez Catalina, Pablo Ponte, Carla Botella, Marta Rodrigues, Joao Esmatjes, Enric Lafita, Javier Lizan, Luis Llorente, Ignacio Morales, Cristobal Navarro-Perez, Jorge Orozco-Beltran, Domingo Paz, Silvia Ramirez de Arellano, Antonio Cardoso, Cristina Tribaldos Causadias, Maribel |
| author_role |
author |
| author2 |
Feliciano, Rosa Fernndez Catalina, Pablo Ponte, Carla Botella, Marta Rodrigues, Joao Esmatjes, Enric Lafita, Javier Lizan, Luis Llorente, Ignacio Morales, Cristobal Navarro-Perez, Jorge Orozco-Beltran, Domingo Paz, Silvia Ramirez de Arellano, Antonio Cardoso, Cristina Tribaldos Causadias, Maribel |
| author2_role |
author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
HbA1c cardiovascular risk diabetes discrete choice model hypoglycemia preferences weight willingness to pay |
| topic |
HbA1c cardiovascular risk diabetes discrete choice model hypoglycemia preferences weight willingness to pay |
| description |
OBJECTIVE: To assess Spanish and Portuguese patients' and physicians' preferences regarding type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain benefits or avoid side effects. METHODS: An observational, multicenter, exploratory study focused on routine clinical practice in Spain and Portugal. Physicians were recruited from multiple hospitals and outpatient clinics, while patients were recruited from eleven centers operating in the public health care system in different autonomous communities in Spain and Portugal. Preferences were measured via a discrete choice experiment by rating multiple T2DM medication attributes. Data were analyzed using the conditional logit model. RESULTS: Three-hundred and thirty (n=330) patients (49.7% female; mean age 62.4 [SD: 10.3] years, mean T2DM duration 13.9 [8.2] years, mean body mass index 32.5 [6.8] kg/m(2), 41.8% received oral + injected medication, 40.3% received oral, and 17.6% injected treatments) and 221 physicians from Spain and Portugal (62% female; mean age 41.9 [SD: 10.5] years, 33.5% endocrinologists, 66.5% primary-care doctors) participated. Patients valued avoiding a gain in bodyweight of 3 kg/6 months (WTP: €68.14 [95% confidence interval: 54.55-85.08]) the most, followed by avoiding one hypoglycemic event/month (WTP: €54.80 [23.29-82.26]). Physicians valued avoiding one hypoglycemia/week (WTP: €287.18 [95% confidence interval: 160.31-1,387.21]) the most, followed by avoiding a 3 kg/6 months gain in bodyweight and decreasing cardiovascular risk (WTP: €166.87 [88.63-843.09] and €154.30 [98.13-434.19], respectively). Physicians and patients were willing to pay €125.92 (73.30-622.75) and €24.28 (18.41-30.31), respectively, to avoid a 1% increase in glycated hemoglobin, and €143.30 (73.39-543.62) and €42.74 (23.89-61.77) to avoid nausea. CONCLUSION: Both patients and physicians in Spain and Portugal are willing to pay for the health benefits associated with improved diabetes treatment, the most important being to avoid hypoglycemia and gaining weight. Decreased cardiovascular risk and weight reduction became the third most valued attributes for physicians and patients, respectively. |
| publishDate |
2015 |
| dc.date.none.fl_str_mv |
2015 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://fisabio.portalinvestigacion.com/publicaciones/4751 |
| url |
https://fisabio.portalinvestigacion.com/publicaciones/4751 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
DOVE MEDICAL PRESS LTD |
| publisher.none.fl_str_mv |
DOVE MEDICAL PRESS LTD |
| dc.source.none.fl_str_mv |
Patient Preference and Adherence ISSN: 1177889X reponame:r-FISABIO. Repositorio Institucional de Producción Científica instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| instname_str |
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| reponame_str |
r-FISABIO. Repositorio Institucional de Producción Científica |
| collection |
r-FISABIO. Repositorio Institucional de Producción Científica |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869403642109362176 |
| score |
15.81155 |